Table III.
Ritonavir Pharmacokinetics with and Without Gastric pH Modulators
| Geometric Mean Ratios (90% CIs) | ||||||
|---|---|---|---|---|---|---|
| PK Parameter | ATV/RTV (Treatment A) |
ATV/RTV + RAB (Treatment B) |
ATV/RTV + RAB + BHCl (Treatment C) |
B vs A | C vs B | C vs A |
| Cmax (ng/mL) | 1,210 ± 392 | 730 ± 254 | 860 ± 272 | 0.602 (0.241-0.861) | 1.21 (0.849-1.74) | 0.731 (0.511-1.05) |
| AUC0-last (ng*hr/mL) | 7,210 ± 1,610 | 4,280 ± 1,180 | 5,180 ± 1,340 | 0.585 (0.460-0.743) |
1.22 (0.960-1.55) |
0.713 (0.562-0.905) |
| Tmax (hr) | 3.0 (1.0-8.0) | 3.0 (2.0-4.0) | 3.0 ± (1.5-6.0) | N/A | N/A | N/A |
Pharmacokinetic parameter data presented as mean ± SD. Tmax is expressed as median (range). CI, confidence interval; PK, pharmacokinetic; ATV, atazanavir; RTV, ritonavir; RAB, rabeprazole; BHCl, betaine hydrochloride; Cmax, maximum plasma concentration; Tmax, time to maximum plasma concentration; AUC0-last, area under the plasma concentration-time curve from time zero to 22 hours.